Bristol Myers Squibb

OPDUALAG

  1. Home
  2.  / 
  3. J Code
  4.  / OPDUALAG – J9298

Manufacturer:

Bristol Myers Squibb

Name:

OPDUALAG

HCPCS Code Descriptor:

Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg

Category:

J Code

HCPCS:

J9298

NDC(s):

00003-7125-11

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

OPDUALAG is an Oncology drug manufactured by Bristol Myers Squibb and administered via the Intravenous route of administration. The J Code: J9298 is aligned to the drug OPDUALAG.

Opdualag belongs to the group of drugs known as antineoplastic combinations and is used to treat certain types of cancer. This drug is a combination two different medications known as nivolumab and relatlimab. Opdualag is administered to the patient via intravenous infusion over the course of 30 minutes. Opdualag is a branded drug manufactured by the Bristol-Myers Squibb Company. Patient assistance programs for Opdualag can be found through Bristol-Myers Squibb’s Access Support.

Access Pricing and More By Registering

HCPCS Added Date:

10/1/22

HCPCS Effective Date:

10/1/22

HCPCS Short Description:

Inj nivol relatlimab 3mg/1mg

Billing and Coding Guide:

https://www.bmsaccesssupport.bmscustomerconnect.com/servlet/servlet.FileDownload?file=00P4z00001ZRYQaEAP

Patient Assistance:

https://www.bmsaccesssupport.bmscustomerconnect.com/patient

OPDUALAG - J9298